Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
62,853.73 +3,871.12 (+6.56%) CMC Crypto 200
1,359.10 +82.12 (+6.43%)
Lucid Diagnostics Inc. (LUCD)
After hours:
- PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Monday, May 13, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued gr
- PR Newswire
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored, prospective, multicenter clinical validation study assessing the performance of Lucid's EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Esophageal Cell Collection Device. T
- PR Newswire
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month. ECAN, a leading patient advocacy organization focused on increasing esophageal cancer education, advocacy, awareness, and research, was founded 15 years ago by Mindy Mintz Mordecai following the t
